ArticleFrontiers in pharmacology2025
Multi-omics analysis reveals Angelica dahurica radix extract alleviates migraine in rats via gut microbiota-metabolome-gut-brain axis regulation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ershiwuwei Shanhu Pill ameliorates cognitive impairment in Alzheimer's disease mice by remodeling gut microbiota and host serum metabolites.Frontiers in aging neuroscience · 2026Article
- Inhibitory effect and safety of Angelica dahurica-Ligusticum sinense extracts against Malassezia furfur and its biofilms.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence links gut-brain axis dysregulation to migraine pathogenesis. Methods: A nitroglycerin (NTG)-induced migraine rat model was established. Migraine behaviors were video-recorded. Enzyme-linked immunosorbent assay (ELISA) was used to quantify neuroinflammatory and neurotransmitter markers (5-HT, CGRP1, TNF-α, NO, PGE2, DA) in plasma and brain tissue. Intestinal barrier integrity was evaluated by immunohistochemical staining of tight junction proteins (Occludin/ZO-1) and hematoxylin-eosin (H&E) staining of colonic tissue. Gut microbiota composition was analyzed via 16S rRNA gene sequencing of fecal samples, and serum metabolomic profiles were characterized using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF MS). Multi-omics data were integrated to identify key therapeutic targets and pathways. Results: Baizhi alleviated migraine behaviors (head-scratching frequency reduced) and normalized neurochemical dysregulation (plasma and brain tissue 5-HT, CGRP1, TNF-α reduced vs. model). It restored intestinal barrier integrity via Occludin/ZO-1 upregulation and suppressed colonic inflammation. Gut microbiota analysis demonstrated that Baizhi increased the abundance of Conclusion: Baizhi alleviates migraine through multi-target coordination: reinforcing gut barrier function, enriching anti-inflammatory
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.